SCHEMBL4665772

SCHEMBL4665772

COc1cccc(-c2cc(Nc3ccc(NS(=O)(=O)c4ccccc4F)cc3)ncn2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.52
CYP2D6 P10635 4/20 0.52
CYP2C19 P33261 4/20 0.52
CLK4 Q9HAZ1 4/20 0.52
CYP3A4 P08684 3/20 0.52
TSHR P16473 3/20 0.52
USP2 O75604 2/20 0.52
CYP2C9 P11712 1/20 0.52
ABL1 P00519 8/20 0.49
BCR P11274 7/20 0.49
BACE1 P56817 2/20 0.48
HSD17B10 Q99714 2/20 0.48
TP53 P04637 1/20 0.48
MAPK1 P28482 1/20 0.48
HIF1A Q16665 1/20 0.48
EGFR P00533 1/20 0.48
ERBB3 P21860 1/20 0.48
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664333 0.91 TP53 (0.49) CYP1A2CYP2D6CYP2C19CLK4CYP3A4
SCHEMBL4663960 0.90 ABL1 (0.57) ABL1BCRBACE1MEN1NPC1
SCHEMBL4664312 0.88 SLC22A12 (0.52) CYP1A2CYP2D6CYP2C19CLK4CYP3A4
SCHEMBL4665707 0.87 CYP1A2 (0.55) CYP1A2CYP2D6CYP2C19CLK4CYP3A4
SCHEMBL17022942 0.84 CYP1A2 (0.69) CYP1A2CYP2D6CYP2C19CLK4CYP3A4
SCHEMBL4663875 0.83 CYP1A2 (0.55) CYP1A2CYP2D6CYP2C19CLK4CYP3A4
SCHEMBL4665836 0.83 AXL (0.48) CYP1A2CYP2D6CYP2C19CLK4CYP3A4
SCHEMBL4109389 0.82 EGFR (0.54) CYP1A2CYP2D6CYP2C19CLK4CYP3A4
SCHEMBL4667528 0.81 ABL1 (0.57) ABL1BCRBACE1MEN1NPC1
SCHEMBL4665847 0.81 ABL1 (0.51) CYP1A2CYP2D6CYP2C19CLK4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 CYP1A2 1215/4885CYP2D6 646/4885CYP2C19 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.